Last reviewed · How we verify
Fluorodeoxyglucose
Fluorodeoxyglucose is a Small molecule drug developed by Yale University. It is currently in Phase 2 development. Also known as: FDG.
Fluorodeoxyglucose, also known as [18F]FDG, is a radiopharmaceutical used in positron emission tomography (PET) imaging. It is a glucose analog that contains the positron-emitting radionuclide fluorine-18, used to study conditions such as solid tumors, lung cancer, breast cancer, and histiocytosis.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Fluorodeoxyglucose |
|---|---|
| Also known as | FDG |
| Sponsor | Yale University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- DDAVP for Pituitary Adenoma (NA)
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (PHASE2)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (PHASE1, PHASE2)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1, PHASE2)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Reliability of the Human Brain Connectome (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluorodeoxyglucose CI brief — competitive landscape report
- Fluorodeoxyglucose updates RSS · CI watch RSS
- Yale University portfolio CI
Frequently asked questions about Fluorodeoxyglucose
What is Fluorodeoxyglucose?
Who makes Fluorodeoxyglucose?
Is Fluorodeoxyglucose also known as anything else?
What development phase is Fluorodeoxyglucose in?
Related
- Manufacturer: Yale University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: FDG
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing